



UPS AND DOWNS: WHY?

▼ **Cypress Bioscience (CYPB)** lost a little more than half of its value as early data from a key Phase 3 clinical trial showed its drug **milnacipran** was statistically ineffective in treating fibromyalgia, a condition which can cause chronic muscle pain and stiffness. Cypress and partner Forest Labs decided to pursue additional Phase 3 clinical trials for the drug.

Prohost comments: To the best of our knowledge, fibromyalgia is a name rather than a disease that has a well established defined etiological factors, pathological pathways, impact and complications. So we do believe that the task of finding a cure is hard. When all lab tests for autoimmune diseases, arthritic diseases and inflammation are negative, the patients who suffer muscular and joint pains are described as having fibromyalgia. As painkillers and anti-inflammatory drugs do not relieve the symptoms, many rheumatologists give their patients either sedatives, or antipsychotic drugs. Good luck for all those who try to bring any product to treat these painful annoying symptoms.

▼ **Incyte (INCY)** lost momentum then tried to rebound on Wednesday, as it has to conduct an additional Phase 2 clinical trial for **Reverset**, its HIV drug.

▲ **Vertex (VRTX- Profile)** crossed the \$20 barrier as it was suppressed before it regains momentum and also because its hepatitis C drug is capturing the attention of analysts. Recently, Prudential announced it was initiating coverage of the stock with an overweight rating and price target of \$25 a share.

IN THE NEWS

We get hundreds of press releases everyday, which can drive the followers crazy before making them rich, or poor. There is a lot of interesting news today, but despite the fact that some look optimistic and others very bad, we kept them in the archive for the sake of comparison with tomorrow's news and after tomorrow impacting surprises. As a matter of fact, by doing so, we try to avoid surprises, which we believe can happen only when we lag behind in doing a careful homework. We brought the following news because it is about **gene therapy**, a subject that we carefully follow, carefully assess and carefully decide upon its success, when it is confirmed.

Neurologix (OTCBB:NRGX-) reported positive interim Results of **gene therapy** clinical trial for patients with Parkinson's Disease. Read details: [Neurologix Announces Positive Interim Results of Landmark Gene Therapy Clinical Trial for Patients with Parkinson's Disease](#)

PROHOST RESEARCH
P.O. BOX 640 429
Oakland Gardens, Ny 11364
Telephone : 516 678 1335 Fax 718 423 2731
E-mail prohost@aol.com.

FORWARD-LOOKING STATEMENT Prohost is independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at: <http://www.sec.gov/consumer/cyberfr.htm>